Literature DB >> 9210757

CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.

R P Sharma1, P G Janicak, G Bissette, C B Nemeroff.   

Abstract

OBJECTIVE: The relationship between CSF neurotensin concentrations and measures of psychopathology in patients with schizophrenia or schizoaffective disorder was examined before and after treatment with antipsychotic drugs.
METHOD: CSF neurotensin concentrations were measured in 42 drug-free patients with schizophrenia or schizoaffective disorder. For 18 of these patients, CSF neurotensin was measure again after 4 weeks of antipsychotic treatment.
RESULTS: Significantly higher levels of pretreatment psychopathology were observed in the patients with the lowest CSF neurotensin concentrations. Furthermore, improvements in overall psychopathology and, particularly, negative symptoms were correlated with increases in CSF neurotensin concentrations during treatment.
CONCLUSIONS: These findings provide further evidence for a role of neurotensin the pathophysiology of psychosis and in the mechanism of action of antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210757     DOI: 10.1176/ajp.154.7.1019

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  33 in total

Review 1.  De Novo delayed onset hypothermia secondary to therapeutic doses of risperidone in bipolar affective disorder.

Authors:  M A Lasitha Perera; Jegan Yogaratnam
Journal:  Ther Adv Psychopharmacol       Date:  2014-04

Review 2.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 3.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Allosteric inhibition of the neuropeptidase neurolysin.

Authors:  Christina S Hines; Kallol Ray; Jack J Schmidt; Fei Xiong; Rolf W Feenstra; Mia Pras-Raves; Jan Peter de Moes; Jos H M Lange; Manana Melikishvili; Michael G Fried; Paul Mortenson; Michael Charlton; Yogendra Patel; Stephen M Courtney; Chris G Kruse; David W Rodgers
Journal:  J Biol Chem       Date:  2014-11-05       Impact factor: 5.157

5.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

6.  Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.

Authors:  E B Binder; B Kinkead; M J Owens; C D Kilts; C B Nemeroff
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

7.  Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism.

Authors:  Dominic Thibault; Paul R Albert; Graciela Pineyro; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

8.  Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions.

Authors:  P E Holtom; P L Needham; G W Bennett; S Aspley
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

9.  Association between neurotensin receptor 1 (NTR1) gene polymorphisms and schizophrenia in a Han Chinese population.

Authors:  Hui Ma; Yinglin Huang; Bo Zhang; Jingying Li; Yuan Wang; Xiaofeng Zhao; Qiu Jin; Gang Zhu
Journal:  J Mol Neurosci       Date:  2013-03-13       Impact factor: 3.444

10.  The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Joanna Peris; Elliott Richelson
Journal:  Brain Res       Date:  2009-11-27       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.